Detalhe da pesquisa
1.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Blood
; 141(11): 1308-1315, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375118
2.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Blood
; 139(17): 2666-2672, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35171994
3.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood
; 139(18): 2747-2757, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511184
4.
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Ann Hematol
; 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443660
5.
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
Am J Hematol
; 98(2): 264-271, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588407
6.
FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
Stroke
; 52(10): e605-e609, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34304603
7.
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Haematologica
; 105(3): 640-651, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31278207
8.
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Haematologica
; 104(3): 497-504, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30287621
9.
Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
Am J Hematol
; 94(12): 1314-1324, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31489694
10.
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Blood
; 127(21): 2569-74, 2016 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27002117
11.
Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.
Blood
; 124(22): 3228-36, 2014 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25293768
12.
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
Br J Haematol
; 170(3): 372-83, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25907546
13.
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
Blood
; 118(16): 4338-45, 2011 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21832276
14.
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
Genes Chromosomes Cancer
; 51(8): 743-55, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22489043
15.
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe.
EJHaem
; 4(1): 45-54, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36819165
16.
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Hematology
; 28(1): 2207948, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133334
17.
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
J Clin Oncol
; 41(19): 3523-3533, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37071836
18.
Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
Eur J Haematol
; 88(3): 249-59, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22023551
19.
FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL.
Clin Hematol Int
; 4(3): 65-74, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36103041
20.
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Leukemia
; 36(10): 2519-2527, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071100